Company
Headquarters: Valbonne, France
Employees: 155
CEO: Mr. Fredrik Brag
€46.5 Million
EUR as of July 1, 2024
US$49.9 Million
Company | Market Cap (USD) |
---|---|
Thermo Fisher Scientific | $204.45 B |
Danaher | $177.21 B |
Siemens Healthineers AG | $63.84 B |
DexCom, Inc. | $45.21 B |
Lonza Group Ltd | $39.85 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Median Technologies SA develops and markets software products and platforms for medical image analysis in France, the United States, Canada, the United Kingdom, China, and internationally. The company offers iBiopsy (Imaging BIOmarker Phenotyping System), a phenomics imaging platform empower translational research with AI powered Biomarker identification tools and inform clinical decisions using CT scan similarity search for patient profiling services; and iSee for image analysis and management in clinical trials. It also provides imaging contract research services, such as study start up, image and clinical data management, scientific consulting, independent reviews, image data processing and site support, and study close-out for studies. Median Technologies SA has a research collaboration agreement with the University of California San Diego to conduct a study for its proprietary imaging platform iBiopsy validation. The company was founded in 2002 and is based in Valbonne, France.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Median Technologies SA has the following listings and related stock indices.
Stock: FSX: 4ZG wb_incandescent
Stock: Euronext: ALMDT wb_incandescent